Loading...
•
Dec 31, 2019
Ocular Therapeutix Q4 2019 Earnings Report
Ocular Therapeutix reported fourth quarter and year end 2019 financial results and provided a business update.
Key Takeaways
Ocular Therapeutix reported a strong end to 2019, with DEXTENZA net product revenue reaching $1.6 million, a 433% increase sequentially. The company is guiding first-quarter total net product revenue of $3.0 million to $3.2 million. Interim clinical data releases for OTX-TIC and OTX-TKI showed favorable safety profiles, tolerability, durability, and early biological activity.
DEXTENZA net product revenue reached $1.6 million, a 433% sequential increase.
The company is guiding first-quarter total net product revenue of $3.0 million to $3.2 million.
Interim clinical data from Phase 1 programs OTX-TIC and OTX-TKI showed favorable results.
OTX-CSI IND was filed, with a Phase 1 clinical trial expected to begin by mid-2020.
Ocular Therapeutix
Ocular Therapeutix
Ocular Therapeutix Revenue by Segment
Revenue by Segment
Product Revenue
CapyFin.com Forward Guidance
The company is guiding first-quarter total net product revenue of $3.0 million to $3.2 million.